Stock Performance and Price Movement
On 19 Jan 2026, Vivimed Labs’ stock price touched its lowest level in the past year, marking a significant milestone in a prolonged period of decline. The stock has been on a continuous downward trajectory for the last 18 trading sessions, resulting in a cumulative loss of approximately 66% over this period. This steep fall has brought the share price well below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling persistent bearish momentum.
Today’s trading session saw the stock underperform its sector by 4.69%, with a day change of -4.91%. The 52-week high for Vivimed Labs was ₹24.01, highlighting the stark contrast to its current valuation at the 52-week low.
Market Context and Broader Indices
The broader market environment has also been challenging. The Sensex opened flat but declined by 371.39 points, or 0.54%, closing at 83,123.10. This marks a third consecutive weekly fall for the index, which has lost 3.08% over the past three weeks. Despite this, the Sensex remains 3.65% below its 52-week high of 86,159.02. The index is trading below its 50-day moving average, although the 50DMA remains above the 200DMA, indicating some underlying resilience in the broader market.
In comparison, Vivimed Labs’ one-year performance stands at 0.00%, significantly lagging behind the Sensex’s 8.48% gain over the same period.
From struggle to strength! This Small Cap from Textile - Machinery is showing early turnaround signals that look promising. Position yourself now for explosive growth potential ahead!
- - Early turnaround signals
- - Explosive growth potential
- - Textile - Machinery recovery play
Position for Explosive Growth →
Financial Health and Fundamental Metrics
Vivimed Labs’ financial indicators reveal several areas of concern that have contributed to the stock’s decline. The company has not declared any financial results in the last six months, which has added to uncertainty around its performance. Its long-term fundamental strength is rated weak, as reflected in the MarketsMOJO Mojo Score of 24.0 and a Mojo Grade of Strong Sell, assigned on 22 Dec 2025.
The company’s ability to service debt is notably constrained, with a high Debt to EBITDA ratio of 12.57 times. This elevated leverage level indicates significant financial risk and pressure on cash flows. The debt-equity ratio, recorded at 9.60 times in the half-year period ending June 2023, further underscores the company’s reliance on borrowed funds.
Profitability metrics also remain subdued. The average Return on Equity (ROE) stands at a modest 1.75%, signalling limited returns generated on shareholders’ funds. Additionally, the company reported a negative Profit After Tax (PAT) of ₹-281.57 crores for the half-year period, representing a decline of 34.93% compared to previous periods. The debtors turnover ratio was also at a low 2.44 times, indicating slower realisation of receivables.
Stock Valuation and Risk Profile
Vivimed Labs is currently trading at valuations that are considered risky relative to its historical averages. Over the past year, the stock has generated no returns, while its profits have contracted by 267.9%. This combination of stagnant share price and deteriorating profitability has contributed to the stock’s downgrade to a Strong Sell rating by MarketsMOJO.
The company’s market capitalisation grade is rated 4, reflecting its relatively small size and limited market presence compared to larger peers. The ongoing decline in share price and financial metrics has heightened concerns about the stock’s near-term stability.
Is Vivimed Labs your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Summary of Key Data Points
To summarise, Vivimed Labs’ stock has experienced a significant decline, culminating in a 52-week low price. The stock’s performance over the last 18 days has been particularly weak, with a 66% loss in value. Financially, the company faces challenges with high leverage, negative profitability trends, and delayed financial disclosures. The broader market context has also been unfavourable, with the Sensex itself under pressure, though it has outperformed Vivimed Labs over the past year.
These factors collectively explain the stock’s current valuation and rating, reflecting a cautious stance on its near-term prospects.
Unlock special upgrade rates for a limited period. Start Saving Now →
